Hassan E - Search Results

1

Management and outcomes of paediatric patients on emicizumab prophylaxis undergoing surgical procedures: Experience from a large haemophilia centre in the UK.

Hassan E, Motwani J. Hassan E, et al. Haemophilia. 2021 Sep;27(5):e620-e623. doi: 10.1111/hae.14358. Epub 2021 Jun 12. Haemophilia. 2021. PMID: 34118116 No abstract available.

2

Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors.

Hassan E, Jonathan L, Jayashree M. Hassan E, et al. Haemophilia. 2021 Nov;27(6):e698-e703. doi: 10.1111/hae.14432. Epub 2021 Oct 10. Haemophilia. 2021. PMID: 34628693

3

Patients on emicizumab prophylaxis with previously tolerized inhibitors: Is there a risk of inhibitors recurrence?

Hassan E, Lancashire J, Motwani J. Hassan E, et al. Haemophilia. 2022 Mar;28(2):e36-e38. doi: 10.1111/hae.14466. Epub 2021 Nov 24. Haemophilia. 2022. PMID: 34821004 No abstract available.

4

Emicizumab in previously untreated and minimally treated infants.

Hassan E, Lancashire J, Motwani J. Hassan E, et al. Haemophilia. 2022 Mar;28(2):e61-e63. doi: 10.1111/hae.14485. Epub 2022 Jan 4. Haemophilia. 2022. PMID: 34981874 No abstract available.

5

Breakthrough bleeding episodes in pediatric severe hemophilia a patients with and without inhibitors receiving emicizumab prophylaxis: a single-center retrospective review.

Hassan E, Motwani J. Hassan E, et al. Pediatr Hematol Oncol. 2022 Aug;39(5):418-426. doi: 10.1080/08880018.2021.2004269. Epub 2022 Feb 16. Pediatr Hematol Oncol. 2022. PMID: 35170384

6

Single centre experience of the use of emicizumab in previously untreated and minimally treated patients under 18 months of age.

Hassan E, Motwani J. Hassan E, et al. Pediatr Blood Cancer. 2024 Jun;71(6):e30941. doi: 10.1002/pbc.30941. Epub 2024 Mar 10. Pediatr Blood Cancer. 2024. PMID: 38462765

7

Impact of the COVID-19 pandemic on health-related quality of life and anxiety in pediatric hematology/oncology patients.

Hassan E, Nagui Rizk D, Aly NM, El Chazli Y. Hassan E, et al. Pediatr Hematol Oncol. 2021 Nov;38(8):683-694. doi: 10.1080/08880018.2021.1922559. Epub 2021 May 11. Pediatr Hematol Oncol. 2021. PMID: 33974490

8

Positive Impact of Clinical Audit on Appropriateness of Laboratory Investigations for Glucose-6-Phosphate Dehydrogenase-Deficient Patients in the Emergency Department.

Hassan E, Foulath G, Abdelghany M, Sayed I, Elkhity D, El Chazli Y. Hassan E, et al. Indian J Pediatr. 2021 Sep;88(9):859-863. doi: 10.1007/s12098-020-03571-x. Epub 2020 Nov 20. Indian J Pediatr. 2021. PMID: 33216322

9

Health status assessment of drug addicts in Alexandria.

Badr II, Farghaly AG, Koura MR, Mohamed HF, Hassan EM, Kotkat AM. Badr II, et al. Among authors: hassan em. J Egypt Public Health Assoc. 1998;73(3-4):275-96. J Egypt Public Health Assoc. 1998. PMID: 17219925

10

Serum level of interleukin-15 in active alopecia areata patients and its relation to age, sex, and disease severity.

El Aziz Ragab MA, Hassan EM, El Niely DAEM, Mohamed MM. El Aziz Ragab MA, et al. Postepy Dermatol Alergol. 2020 Dec;37(6):904-908. doi: 10.5114/ada.2020.102103. Epub 2021 Jan 6. Postepy Dermatol Alergol. 2020. PMID: 33603607 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

692 results

Search Page

Filters